Fast Market Research

New Market Study: "Engaging Key Opinion Leaders (KOLs) - Identifying and Leveraging New KOL Groups to Drive Medical Marketing Strategy"

Fast Market Research recommends "Engaging Key Opinion Leaders (KOLs) - Identifying and Leveraging New KOL Groups to Drive Medical Marketing Strategy" from GBI Research, now available

 

Boston, MA -- (ReleaseWire) -- 11/09/2012 -- GBI Research, the leading business intelligence provider, has released its latest research, "Engaging Key Opinion Leaders (KOLs) - Identifying and Leveraging New KOL Groups to Drive Medical Marketing Strategy". This report examines the roles of Key Opinion Leaders (KOLs) within the pharmaceutical industry now and in the future. It looks at the roles traditionally held by KOLs. It describes the consequences of the changing healthcare environment on how the industry identifies and works with new groups of key opinion leaders, examining three areas of particular importance for KOL management within the pharmaceutical industry today. Firstly, the report will investigate the emerging trend to externalize research and to establish productive relationships with academic laboratories and principal investigators. Secondly, it will analyze the landscape for the traditional KOL - the healthcare professional - detailing changes to Codes of Practice guiding the pharmaceutical industry's interactions with these individuals, trends in KOL management, and issues of relevance to emerging markets. Finally, the report considers the role of patients and their advocates in providing insights that should drive drug discovery and development in the future.

View Full Report Details and Table of Contents

The report is built using information from primary and secondary research, including interviews with experts in the field.

GBI Research analysis shows that the pharmaceutical industry is facing a number of challenges that will influence the way it works with KOLs. The costs of R&D are rising as clinical development programs become longer and more complex, while industry revenues are falling. Companies have cut their internal workforces and are now looking externally for new products. The pressure on healthcare budgets from growing and ageing populations and the rise in non-communicable diseases, such as cardiovascular disease and different cancers, as well as the increasing costs of some medicines, have led healthcare providers to pay much greater attention to the cost-effectiveness of new products as a condition of reimbursement. As a consequence, the focus on marketing medicines in emerging economies has also increased. These changes require reevaluation of the role of the KOL as new groups of thought leaders are considered highly influential to the future of the industry.

Scope

- Detailed analysis of the changes in the industry and healthcare environment that are causing new groups of KOLs to emerge
- Exploration of the influence of academic scientists on industry R&D as companies look to externalize more of their research
- Detailed insights into the changing nature of the relationship of the industry with healthcare professionals, including details of the current compliance environment
- Examination of the role of patients in driving drug development within the industry

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Bayer HealthCare Pharmaceuticals - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- F. Hoffmann-La Roche Ltd. (ROG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Sanofi-Aventis (SANN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Boston Scientific Corporation (BSX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Amgen Inc. (AMGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Abbott Laboratories (ABT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Millennium Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile